The primary objectives of the Biostatistics Unit (BU) are to provide centralized expertise in the statistical aspects of clinical and basic research, and in database management. Specifically, personnel in this Unit consult on the design and analysis of clinical and basic research studies; help develop and implement data management systems for research studies; participate in the development, enhancement, and integration of various information systems including the Cancer Center's new clinical information system, the OSU Hospitals' computer network, and OSU Hospitals' Cancer Registry; provide assistance in the use of other biostatistical and computational resources on campus; and conduct educational Programs for faculty, students, and staff. According to Summary 4, services are provided to 11 peer-reviewed funded projects from 7 of the 13 Cancer Center Programs, 10 CTEP protocols, and numerous developing projects. More than 100 investigators were served by the BU during 1992-1993. The BU is located on the 11th floor of the James Cancer Hospital and Research Institute in close proximity to research laboratories and clinical units. All patients enrolled on clinical trials are registered in a Clinical Information System written in the MIIS-MUMPS database language running on a Data General computer. This system will be converted to a relational database running on a VAX computer that is located in the General Clinical Research Center (GCRC). Additional biostatistical and computer expertise is available from eight other units on and off campus. In addition, a new Biostatistical Center is being designed in collaboration between the Department of Statistics, the Department of Preventive Medicine, and the BU. A campus-wide communications network provides E-mail connections and access to the Internet.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-21
Application #
3729039
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
21
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications